Generics With Poor Bioavailability May Not Use 505(b)(2) "Paper" NDA

Generic drug applicants may not use the paper NDA 505(b)(2) mechanism of approval for products that have a reduced rate of absorption compared to the innovator, FDA said in its "Guidance for Industry: Applications Covered by Section 505(b)(2)."